{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:28:49Z","timestamp":1772166529019,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016240","name":"Nihon Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016240","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jdermsci.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T02:21:48Z","timestamp":1673490108000},"page":"22-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Intravenous immunoglobulin in patients with bullous pemphigoid insufficient response to corticosteroids: Nationwide post-marketing surveillance in Japan"],"prefix":"10.1016","volume":"109","author":[{"given":"Hideyuki","family":"Ujiie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2023.01.004_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2023.01.004_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","article-title":"Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management","volume":"54","author":"Amber","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib3","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/1346-8138.15111","article-title":"Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)","volume":"46","author":"Ujiie","year":"2019","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British Association of Dermatologists, British Association of Dermatologists\u2019 guidelines for the management of bullous pemphigoid 2012","volume":"167","author":"Venning","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib7","first-page":"CD002292","article-title":"Interventions for bullous pemphigoid","volume":"2012","author":"Kirtschig","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib9","unstructured":"Review Report, Pharm Devices Agency, 2015. \u3008https:\/\/www.pmda.go.jp\/files\/000223353.pdf\u3009."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2133.2004.06082.x","article-title":"Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid","volume":"151","author":"Sakuma-Oyama","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archderm.138.7.903","article-title":"Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age","volume":"138","author":"Rzany","year":"2002","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2340\/00015555-2473","article-title":"The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use?","volume":"97","author":"Wijayanti","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib15","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/bjd.19611","article-title":"International validation of the Bullous pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000362717","article-title":"Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients","volume":"229","author":"L\u00e9vy-Sitbon","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.jdermsci.2023.01.004_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamadermatol.2013.5757","article-title":"Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study","volume":"150","author":"Fichel","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib18","doi-asserted-by":"crossref","unstructured":"E. Pasmatzi, A. Monastirli, J. Habeos, S. Georgiou, D. Tsambaos, Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases, Diabetes Care, vol. 34(no. 201), e133.","DOI":"10.2337\/dc11-0804"},{"key":"10.1016\/j.jdermsci.2023.01.004_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamadermatol.2013.1073","article-title":"A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors","volume":"149","author":"Aouidad","year":"2013","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. a case report and review of literature","volume":"8","author":"Attaway","year":"2014","journal-title":"J. Dermatol. Case Rep."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French pharmacovigilance Database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: a systematic review and meta-analysis","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib23","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.2337\/dc18-0210","article-title":"Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database","volume":"41","author":"Arai","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdermsci.2023.01.004_bib24","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","article-title":"HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors","volume":"138","author":"Ujiie","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib26","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/1346-8138.15778","article-title":"Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: a comparative study of 100 patients with bullous pemphigoid and diabetes mellitus","volume":"48","author":"Chanprapaph","year":"2021","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib27","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3390\/jcm10091916","article-title":"Clinical, laboratory and histological features of dipeptidyl peptidase-4 inhibitor related noninflammatory bullous pemphigoid","volume":"10","author":"Kiny\u00f3","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib28","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1172\/JCI116856","article-title":"A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180","volume":"92","author":"Liu","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib29","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1684\/ejd.2018.3366","article-title":"Immunoglobulin E and bullous pemphigoid","volume":"28","author":"Cozzani","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdermsci.2015.01.013","article-title":"In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases","volume":"78","author":"Moriuchi","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib33","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/08916934.2011.606447","article-title":"Pemphigoid diseases: pathogenesis, diagnosis, and treatment","volume":"45","author":"Kasperkiewicz","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jdermsci.2023.01.004_bib35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.autrev.2014.01.011","article-title":"Diagnosis and classification of pemphigus and bullous pemphigoid","volume":"13","author":"Kershenovich","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/exd.12146","article-title":"Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida","volume":"22","author":"Iwata","year":"2013","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib37","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib38","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jid.2018.02.020","article-title":"Modes of action of intravenous immunoglobulin in bullous pemphigoid","volume":"138","author":"Li","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib40","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/09546634.2020.1737638","article-title":"Off-label dermatologic uses of IL-17 inhibitors","volume":"33","author":"Wu","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib43","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib44","article-title":"Commentary: efficacy and safety of Dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib45","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3389\/fimmu.2019.01090","article-title":"High-dose intravenous immunoglobulin in skin autoimmune disease","volume":"10","author":"Hoffmann","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jdermsci.2023.01.004_bib46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/trf.14419","article-title":"Intravenous immunoglobulin-induced acute thrombocytopenia","volume":"58","author":"Gurevich-Shapiro","year":"2018","journal-title":"Transfusion"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092318112300004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092318112300004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:52:46Z","timestamp":1760331166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092318112300004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S092318112300004X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2023.01.004","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulin in patients with bullous pemphigoid insufficient response to corticosteroids: Nationwide post-marketing surveillance in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}